Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Keryx Biopharmaceuticals Inc (NASDAQ:KERX)

6.08
BATS BZX Real-Time Price
As of 11:01am ET
 +0.12 / +2.01%
Today’s Change
2.80
Today|||52-Week Range
7.80
+20.40%
Year-to-Date
This Is Why Keryx Biopharmaceuticals Surged 28% in November
Dec 06 / MotleyFool.com - Paid Partner Content
3 Biotech Investing Tips That Could Earn You Thousands
Nov 28 / MotleyFool.com - Paid Partner Content

Today’s Trading

Previous close5.96
Today’s open6.00
Day’s range5.99 - 6.20
Volume11,673
Average volume (3 months)1,576,441
Market cap$631.5M
Dividend yield--
Data as of 11:01am ET, 12/09/2016

Growth & Valuation

Earnings growth (last year)+3.25%
Earnings growth (this year)-17.99%
Earnings growth (next 5 years)+30.00%
Revenue growth (last year)+26.37%
P/E ratioNM
Price/Sales38.35
Price/Book7.21

Competitors

 Today’s
change
Today’s
% change
ENTAEnanta Pharmaceutica...+0.53+1.61%
PGNXProgenics Pharmaceut...+0.12+1.35%
FLXNFlexion Therapeutics...+0.11+0.56%
GBTGlobal Blood Therape...+0.05+0.31%
Data as of 11:00am ET, 12/09/2016

Financials

Next reporting dateMarch 14, 2017
EPS forecast (this quarter)-$0.21
Annual revenue (last year)$13.7M
Annual profit (last year)-$123.1M
Net profit margin-900.18%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer &
Director
Gregory P. Madison
Chief Financial Officer
Scott A. Holmes
Corporate headquarters
Boston, Massachusetts

Forecasts


Search for Jobs